<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a now 13-year-old male with <z:mp ids='MP_0004027'>trisomy</z:mp> 21, <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo>, and <z:mp ids='MP_0002056'>insulin-dependent diabetes</z:mp> who developed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002301'>hemiplegia</z:hpo> due to the <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APS) at age four </plain></SENT>
<SENT sid="1" pm="."><plain>The risks of long-term anticoagulation were initially considered to be high; hence, he was treated with monthly infusions of intravenous immunoglobulin (IVIG) at 2 g/kg for 2 years and then every other month for 7 years </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> were no longer detectable within 6 months and have continued to be negative </plain></SENT>
<SENT sid="3" pm="."><plain>There was no clinical deterioration or further changes on magnetic resonance arteriography over 7 years </plain></SENT>
<SENT sid="4" pm="."><plain>IVIG may be an alternative therapeutic choice for children with APS who are not candidates for conventional anticoagulation </plain></SENT>
</text></document>